Intelligence Feed event · Equity · 2026-10-13

    Abbott Schedules Q3 Earnings for Oct 21 With Consensus Forecasting $1.42 EPS

    Question

    Abbott Schedules Q3 Earnings for Oct 21 With Consensus Forecasting $1.42 EPS

    Direct answer

    Abbott shares outperformed broader benchmarks on October 12, gaining 2.23% to $101.82. The company is set to announce its third-quarter financial results on October 21, 2026. Consensus projections model EPS of $1.42, marking a 9.23% year-over-year improvement, alongside top-line revenue expansion of 13.52% to $12.91 billion. Abbott holds a Zacks Rank #2 (Buy) rating ahead of the release.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-13
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Abbott Schedules Q3 Earnings for Oct 21 With Consensus Forecasting $1.42 EPS”, revision 1, evidence through 2026-10-13. https://marketontology.com/market-events/2026-10-13/abbott-schedules-q3-earnings-for-oct-21-with-consensus-forecasting-1-42-eps-f7f67d

    EQUITY
    Abbott Schedules Q3 Earnings for Oct 21 With Consensus Forecasting $1.42 EPS
    Abbott shares outperformed broader benchmarks on October 12, gaining 2.23% to $101.82. The company is set to announce its third-quarter financial results on October 21, 2026. Consensus projections model EPS of $1.42, marking a 9.23% year-over-year improvement, alongside top-line revenue expansion of 13.52% to $12.91 billion. Abbott holds a Zacks Rank #2 (Buy) rating ahead of the release.
    ABT
    Impact
    61
    OCT 13
    SIG
    81%
    ABT
    Abbott Schedules Q3 Earnings for Oct 21 With Consensus Forecasting $1.42 EPS
    Abbott shares outperformed broader benchmarks on October 12, gaining 2.23% to $101.82. The company is set to announce its third-quarter financial results on October 21, 2026. Consensus projections model EPS of $1.42, marking a 9.23% year-over-year improvement, alongside top-line revenue expansion of 13.52% to $12.91 billion. Abbott holds a Zacks Rank #2 (Buy) rating ahead of the release.
    → Top-line revenue expansion of 13.52% to $12.91 billion flows through to operating margins for ABT ahead of October 21 reporting.
    Impact
    Abbott shares outperformed broader benchmarks on October 12, gaining 2.23% to $101.82. The company is set to announce its third-quarter financial results on October 21, 2026. Consensus projections model EPS of $1.42, marking a 9.23% year-over-year improvement, alongside top-line revenue expansion of 13.52% to $12.91 billion. Abbott holds a Zacks Rank #2 (Buy) rating ahead of the release.
    Affected
    ABT
    Transmission
    Top-line revenue expansion of 13.52% to $12.91 billion flows through to operating margins for ABT ahead of October 21 reporting.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    ABTmedical device and diagnostics volume expansion flowing to quarterly revenueUp1-4wProjected Q3 EPS of $1.42 (+9.23%) on $12.91B revenue (+13.52%)

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month